Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 347-354

  Brown, Lindsay A ^a   Johnson, Karynn ^a   Leung, Samuel ^a   Bismar, Tarek A ^b   Benítez, Javier ^c   Foulkes, William D ^d   Huntsman, David G ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Breast cancer; Gene amplification; Tissue microarray

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EMSY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CHROMOSOME 11Q; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MUTATION RATE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TREATMENT OUTCOME;

BREAST NEOPLASMS; CYCLIN D1; FEMALE; GENE AMPLIFICATION; GENES, BRCA1; GENES, BRCA2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL ANALYSIS; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77953024302     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0479-x     Document Type: Article

References (43)

1. Peters G, Fantl V, Smith R, Brookes S, Dickson C (1995) Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treat 33(2): 125-135
2. Schwab M (1998) Amplification of oncogenes in human cancer cells. Bioessays 20(6):473-479 (Pubitemid 28320609)
3. Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, Kelley PM, Pebusque MJ, Theillet C, Birnbaum D et al (1997) Detailed map of a region commonly amplified at 11q13->q14 in human breast carcinoma. Cytogenet Cell Genet 79(1-2): 125-131
4. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C (1997) Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 57(19)4360-4367 (Pubitemid 27413447)
5. Karlseder J, Zeillinger R, Schneeberger C, Czerwenka K, Speiser P, Kubista E, Birnbaum D, Gaudray P, Theillet C (1994) Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes Cancer 9(1):42-48 (Pubitemid 24007495)
6. Hui R, Ball JR, Macmillan RD, Kenny FS, Prall OW, Campbell DH, Cornish AL, McClelland RA, Daly RJ, Forbes JF et al (1998) EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 17(8): 1053-1059
7. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7(5):812-821 (Pubitemid 23163585)
8. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL (2003) Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78(3):323-335
9. Champeme MH, Bieche I, Lizard S, Lidereau R (1995) 11q13 amplification in local recurrence of human primary breast cancer. Genes Chromosomes Cancer 12(2): 128-133
10. Lammie GA, Peters G (1991) Chromosome 11q13 abnormalities in human cancer. Cancer Cells 3(11)413-420
11. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene 8(8):21.27-21.33 (Pubitemid 23226946)
12. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54(7):1812-1.817 (Pubitemid 24116192)
13. Bieche I, Olivi M, Nogues C, Vidaud M, Lidereau R (2002) Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 86(4):580-586 (Pubitemid 34185096)
14. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J (1996) A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73(6):728-734 (Pubitemid 26105298)
15. Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ, Sutherland RL (1996) Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 2(7): 1177-1184 (Pubitemid 26238449)
16. Kilker RL, Planas-Silva MD (2006) Cyclin D1 is necessary for tamoxifen-induced cell cycle progression, in human, breast cancer cells. Cancer Res 66(23): 11478-11484 (Pubitemid 46009981)
17. Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, Landberg G (2005) Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65(17):8009-8016 (Pubitemid 41297281)
18. Vadlamudi RK, Adam L, Wang RA, Mandai M, Nguyen D, Sahin A, Chernoff J, Hung MC, Kumar R (2000) Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 275(46):36238-36244
19. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, King W, Wilber K, Mihatsch MJ, Moch H (2003) Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 163(3):985-992 (Pubitemid 37040134)
20. Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B et al (2006) Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100(2):264-270
21. Brown LA, Kalloger SE, Miller MA, Shih I.e. M, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB et al (2008) Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 47(6)481-489
22. Balasenthil S, Barnes CJ, Rayala SK, Kumar R (2004) Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett 567(2-3):243-247 (Pubitemid 38748399)
23. Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O (2007) Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26(49):6997-7005 (Pubitemid 350014611)
24. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B et al (2003) EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115(5):523-535
25. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368-1376 (Pubitemid 351413917)
26. Rodriguez C, Hughes-Davies L, Valles H, Orsetti B, Cuny M, Ursule L, Kouzarides T, Theillet C (2004) Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 10(17):5785-5791 (Pubitemid 39180956)
27. Kirkegaard T, Nielsen KV, Jensen LB, Campbell FM, Muller S, Tovey SM, Brown S, Cooke TG, Bartlett JM (2008) Genetic alterations of CCND1 and EMSY in breast cancers. Histopathology 52(6):698-705 (Pubitemid 351600044)
28. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G (2006) Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 98(10):671-680 (Pubitemid 43821785)
29. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y et al (1.994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266(5182): 120-122
30. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G et al (1996) BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13(2):238-240
31. Sorlie T, Andersen TI, Bukholm I, Borresen-Dale AL (1998) Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases. Breast Cancer Res Treat 48(3):259-264 (Pubitemid 28159953)
32. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60(19): 5329-5333
33. Catteau A, Harris WH, Xu CF, Solomon E (1999) Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18(11): 1957-1965 (Pubitemid 29150082)
34. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA et al (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92(7):564-569
35. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE (2002) Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94(1):61-67 (Pubitemid 34082844)
36. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW (2000) Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21(9):1761-1765
37. Collins N, Wooster R, Stratton MR (1997) Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 76(9): 1150-1156 (Pubitemid 27448010)
38. Gras E, Cortes J, Diez O, Alonso C, Matias-Guiu X, Baiget M, Prat J (2001) Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer 92(4):787-795
39. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE (2002) Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94(18):1396-1406 (Pubitemid 35154144)
40. King MC (2004) A novel BRCA2-binding protein and breast and ovarian tumorigenesis. N Engl J Med 350(12): 1252-1253 (Pubitemid 38339370)
41. Livingston DM (2004) EMSY, a BRCA-2 partner in crime. Nat Med 10(2):127-128
42. Vaziri SA, Tubbs RR, Darlington G, Casey G (2001) Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol 54(4):259-263 (Pubitemid 32730403)
43. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C et al (2005) Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90(1):5-14